# OPHN1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *OPHN1* gene, located at Xq12, encodes oligophrenin-1, a Rho GTPase-activating protein (RhoGAP) crucial for central nervous system development and synaptic plasticity. Loss-of-function mutations are a primary cause of X-linked intellectual disability (XLID) with cerebellar hypoplasia.
- OPHN1 functions as a molecular scaffold integrating actin cytoskeleton remodeling, synaptic receptor trafficking (particularly AMPA receptors), endocytosis, and activity-dependent dendritic spine morphogenesis through its BAR-PH-GAP domain architecture.
- Pathogenic mutations, frequently occurring in the RhoGAP domain (e.g., p.Arg489Gly), lead to constitutive RhoA activation, impaired endocytosis, and aberrant spine morphology, contributing to intellectual disability, epilepsy, and autism spectrum disorder features.
- Therapeutic strategies under investigation include Rho kinase (ROCK) inhibitors (e.g., Fasudil), mTORC1 inhibitors (e.g., rapamycin), gene therapy using AAV vectors, and antisense oligonucleotides (ASOs) to restore OPHN1 function.
- OPHN1 plays a role in host-pathogen interactions, with viruses like HSV-1 and HIV-1 manipulating its signaling pathways to facilitate viral replication and spread, contributing to neuroinflammation and cognitive deficits.

---

## Executive Summary & Key Metadata

The **OPHN1** gene (oligophrenin-1) encodes a Rho-GTPase-activating protein (RhoGAP) that is indispensable for the development and functional plasticity of the central nervous system. Germline loss-of-function mutations in OPHN1 are a well-established cause of X-linked intellectual disability (XLID) with cerebellar hypoplasia. Beyond its canonical role in actin cytoskeleton remodeling, OPHN1 operates as a molecular scaffold integrating synaptic receptor trafficking, endocytosis, and activity-dependent dendritic spine morphogenesis. This reference manual provides a comprehensive, biophysically grounded analysis of the OPHN1 locus, its protein domain architecture, signaling networks, pathogenic mutation spectrum, and emerging therapeutic avenues.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | OPHN1 |
| **UniProt Accession** | O60890 |
| **Representative PDB ID** | true (multiple structures available; see Section 2) |
| **Chromosomal Locus** | Xq12 (GRCh38: X:68,042,634–68,142,775) |
| **Primary Molecular Function** | Rho GTPase-activating protein (RhoGAP) activity; regulates actin cytoskeleton dynamics, endosomal trafficking, and synaptic plasticity |
| **Disease & Pathology Associations** | X-linked intellectual disability (OMIM #300486), cerebellar hypoplasia, epilepsy, autism spectrum disorder (ASD) features, and potential tumor-suppressive roles in certain cancers |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

OPHN1 is located on the long arm of the X chromosome at cytogenetic band **Xq12**. The gene spans approximately 100 kilobases (kb) of genomic DNA on the forward (plus) strand. The reference genome assembly (GRCh38) places the transcription start site (TSS) at chrX:68,042,634 and the termination site at chrX:68,142,775. The gene is composed of **23 exons** and **22 introns**, with the translational start codon (ATG) located in exon 2 and the stop codon in exon 23. The 5' untranslated region (UTR) is relatively short (~200 bp), whereas the 3' UTR is extensive (~3.5 kb), containing multiple AU-rich elements (AREs) and binding sites for microRNAs (e.g., miR-132 and miR-134), which are known to regulate OPHN1 expression in a neuronal activity-dependent manner.

### 1.2 Promoter Architecture and Regulatory Elements

The proximal promoter of OPHN1 lacks a canonical TATA box but contains a high-density CpG island spanning from approximately -800 bp to +200 bp relative to the TSS. This CpG island is subject to dynamic DNA methylation, which has been shown to modulate OPHN1 expression in response to neuronal depolarization. Transcription factor binding site (TFBS) analysis reveals conserved motifs for:

- **Sp1/KLF family**: Multiple GC-box elements critical for basal transcription.
- **CREB (cAMP response element-binding protein)**: A functional cAMP response element (CRE) at position -350 bp, which mediates activity-dependent transcription via the PKA/CaMKIV signaling axis.
- **MEF2 (myocyte enhancer factor-2)**: Binding sites in the first intron, which act as enhancers for activity-dependent gene expression in hippocampal neurons.
- **RE1-silencing transcription factor (REST/NRSF)**: A repressor element located in intron 1, which restricts OPHN1 expression in non-neuronal tissues.

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project indicate that the OPHN1 promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer) in human cortical neurons, but is repressed by H3K27me3 in fibroblasts, confirming its neuron-specific expression pattern.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of OPHN1 produces at least **five distinct transcript variants**, which are differentially expressed across brain regions and developmental stages:

| **Isoform** | **Exon Composition** | **Protein Length (aa)** | **Distinct Features** |
| :--- | :--- | :--- | :--- |
| **OPHN1-001 (Canonical)** | Exons 1–23 | 802 | Full-length RhoGAP domain; predominant in adult brain |
| **OPHN1-002** | Exons 1–22 (skips exon 15) | 752 | Lacks a 50-aa segment within the BAR domain; altered membrane curvature sensing |
| **OPHN1-003** | Exons 1–21 (skips exons 15–16) | 701 | Truncated GAP domain; dominant-negative activity in vitro |
| **OPHN1-004** | Exons 1–14, 17–23 | 690 | Retains GAP domain but lacks central PH domain; mislocalizes to cytoplasm |
| **OPHN1-005** | Exons 1–13 (intron 13 retention) | 450 | C-terminal truncation; produces a soluble, non-membrane-bound protein |

The canonical isoform (802 amino acids) is the most abundant in the cerebral cortex, hippocampus, and cerebellum. Isoform switching from OPHN1-005 (fetal) to OPHN1-001 (adult) occurs during synaptogenesis, suggesting a developmental role for the shorter isoform in early neuronal migration.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The OPHN1 protein (UniProt O60890) is a 802-amino-acid polypeptide with a molecular weight of ~88 kDa. It belongs to the BAR (Bin/Amphiphysin/Rvs) domain superfamily of membrane-curvature sensors and RhoGAP proteins. The domain architecture from N-terminus to C-terminus is as follows:

1. **N-terminal BAR domain (aa 1–250)**: A banana-shaped, dimeric α-helical coiled-coil domain that binds to curved membranes (e.g., endocytic vesicles and dendritic spines). The BAR domain senses and induces membrane curvature, facilitating the formation of tubular endosomal intermediates.
2. **PH (Pleckstrin Homology) domain (aa 251–370)**: Inserted within the BAR domain (forming a BAR-PH tandem module). The PH domain binds phosphoinositides, specifically phosphatidylinositol-4,5-bisphosphate (PIP2) and phosphatidylinositol-3,4,5-trisphosphate (PIP3), anchoring OPHN1 to the plasma membrane and endosomal compartments.
3. **RhoGAP domain (aa 371–550)**: The catalytic core that accelerates GTP hydrolysis on Rho family GTPases (RhoA, Rac1, and Cdc42). The GAP domain adopts a canonical α-helical bundle architecture with a conserved arginine finger (Arg489) that stabilizes the transition state of GTP hydrolysis.
4. **C-terminal proline-rich region (aa 551–802)**: Contains multiple PXXP motifs that mediate interactions with SH3-domain-containing proteins (e.g., amphiphysin, endophilin, and dynamin). This region also harbors a nuclear localization signal (NLS) and a C-terminal PDZ-binding motif (ETSV), which interacts with synaptic scaffolding proteins such as PSD-95 and SAPAP.

### 2.2 Structural Biology and 3D Conformation

High-resolution structural studies using X-ray crystallography and cryo-electron microscopy (cryo-EM) have resolved the BAR-PH-GAP module. The BAR domain forms an antiparallel dimer, creating a positively charged concave surface that interacts with negatively charged phospholipid headgroups. The PH domain is positioned at the membrane interface, where it inserts a flexible loop into the lipid bilayer to sense PIP2 concentration.

The RhoGAP domain is connected to the BAR-PH module via a flexible linker (aa 340–370), allowing the GAP domain to sample multiple orientations relative to the membrane. This conformational plasticity is critical for the enzyme's ability to act on membrane-bound Rho GTPases. The catalytic arginine finger (Arg489) is positioned within a shallow groove that accommodates the Switch I and Switch II regions of RhoA. Mutations that disrupt the arginine finger (e.g., R489G) abolish GAP activity, leading to constitutive RhoA activation and actin polymerization defects.

> **Interactive 3D Protein Visualizer: Load OPHN1 (PDB: true)**
> [Interactive 3D Protein Visualizer: Load OPHN1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O60890)
> Use the visualizer to explore the BAR-PH-GAP domain arrangement, rotate the dimer interface, and highlight the Arg489 catalytic residue.

### 2.3 Post-Translational Modifications (PTMs)

OPHN1 is subject to extensive post-translational regulation:

- **Phosphorylation**: CDK5 phosphorylates Ser298 and Thr300 within the PH domain, reducing membrane binding affinity. CaMKII phosphorylates Ser579 in the proline-rich region, enhancing binding to endophilin and promoting AMPA receptor endocytosis.
- **Ubiquitination**: The E3 ligase MDM2 ubiquitinates OPHN1 at Lys residues in the GAP domain, targeting it for proteasomal degradation. This pathway is activated during chronic stress and contributes to dendritic spine loss.
- **Sumoylation**: SUMO1 conjugation at Lys411 modulates nuclear-cytoplasmic shuttling, with implications for transcriptional regulation in neurons.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Rho GTPase Regulation and Actin Dynamics

OPHN1 is a negative regulator of RhoA, Rac1, and Cdc42. By accelerating the intrinsic GTPase activity of these small G-proteins, OPHN1 promotes the conversion of the active GTP-bound state to the inactive GDP-bound state. This activity is essential for:

- **Dendritic spine morphogenesis**: RhoA activation leads to actin stress fiber formation and spine retraction, whereas OPHN1-mediated RhoA inactivation promotes spine head expansion and stabilization. Loss of OPHN1 results in elongated, filopodia-like spines with reduced postsynaptic density (PSD) area.
- **Axonal growth cone guidance**: OPHN1 coordinates Rac1 and Cdc42 signaling to regulate lamellipodia and filopodia dynamics, respectively. This is critical for proper axon pathfinding during development.
- **Cell migration**: In neural progenitors, OPHN1 modulates RhoA activity to control radial migration from the ventricular zone to the cortical plate.

### 3.2 Endocytosis and Receptor Trafficking

OPHN1 is a core component of the clathrin-mediated endocytosis (CME) machinery. Through its BAR domain, it binds to dynamin, amphiphysin, and endophilin, facilitating the scission of endocytic vesicles. In glutamatergic synapses, OPHN1 specifically regulates the endocytosis of AMPA-type glutamate receptors (AMPARs). This process is activity-dependent:

1. Upon synaptic stimulation, CaMKII phosphorylates OPHN1 at Ser579.
2. Phosphorylated OPHN1 recruits endophilin to the plasma membrane.
3. Endophilin, in complex with dynamin, drives the internalization of AMPARs, leading to long-term depression (LTD).

Loss of OPHN1 impairs AMPAR endocytosis, resulting in enhanced basal synaptic transmission and impaired LTD. This molecular defect is believed to underlie the cognitive deficits observed in patients with OPHN1 mutations.

### 3.3 Interaction with the mTOR and Wnt Pathways

Recent proteomic studies have identified OPHN1 as a negative regulator of the mTORC1 signaling pathway. OPHN1 binds to the TSC1-TSC2 complex (tuberous sclerosis complex), stabilizing it and promoting the inactivation of Rheb, a direct activator of mTORC1. In OPHN1-deficient neurons, mTORC1 is hyperactivated, leading to excessive protein synthesis and aberrant synaptic scaling. This crosstalk positions OPHN1 as a central node linking Rho GTPase signaling to translational control.

Additionally, OPHN1 interacts with Dishevelled (Dvl) in the Wnt/β-catenin pathway. OPHN1 promotes Dvl degradation via the proteasome, thereby inhibiting Wnt-induced transcriptional programs. In the developing cortex, this interaction regulates the balance between neural progenitor proliferation and differentiation.

### 3.4 Protein-Protein Interaction Network

STRING and BioGRID analyses reveal a dense interactome centered on OPHN1:

| **Interactor** | **Domain/Motif** | **Functional Consequence** |
| :--- | :--- | :--- |
| RhoA, Rac1, Cdc42 | RhoGAP domain | GTP hydrolysis; actin remodeling |
| Dynamin-1 | Proline-rich region | Endocytosis; vesicle scission |
| Amphiphysin-1/2 | Proline-rich region | Clathrin-mediated endocytosis |
| Endophilin-A1/A2 | Proline-rich region | AMPAR internalization |
| PSD-95 | PDZ-binding motif | Synaptic scaffolding |
| TSC1/TSC2 | GAP domain | mTORC1 inhibition |
| Dvl1-3 | BAR domain | Wnt pathway inhibition |
| CDK5 | PH domain | Phosphorylation; membrane dissociation |

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant NT as "Neurotransmitter (Glutamate)"
    participant R as "AMPA Receptor"
    participant C as "CaMKII"
    participant O as "OPHN1"
    participant E as "Endophilin/Dynamin"
    participant A as "Actin Cytoskeleton"
    participant M as "mTORC1"
    NT->>R: Binds and activates
    R->>C: Ca2+ influx, CaMKII activation
    C->>O: Phosphorylates Ser579
    O->>E: Recruits endophilin complex
    E->>R: Internalizes AMPA receptor (LTD)
    O->>A: Inactivates RhoA (spine stabilization)
    O->>M: Inhibits mTORC1 (translational control)
    Note over O: Loss of OPHN1 leads to<br/>spine elongation, mTORC1<br/>hyperactivation, and impaired LTD
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutation Spectrum in X-Linked Intellectual Disability

OPHN1 mutations account for approximately 1–2% of all cases of X-linked intellectual disability (XLID). Over 60 distinct pathogenic variants have been reported in the ClinVar and HGMD databases. These include missense, nonsense, frameshift, and splice-site mutations, as well as whole-gene deletions.

#### 4.1.1 Missense Mutations in the RhoGAP Domain

The RhoGAP domain is a major hotspot for pathogenic missense mutations. The most frequently reported variants include:

- **p.Arg489Gly (c.1465C>G)**: Substitution of the catalytic arginine finger. This mutation abolishes GAP activity, leading to constitutive RhoA activation. Patients present with severe intellectual disability, cerebellar hypoplasia, and seizures.
- **p.Leu323Pro (c.968T>C)**: Located in the PH domain, this mutation disrupts PIP2 binding, causing mislocalization of OPHN1 from the plasma membrane to the cytoplasm.
- **p.Thr340Ile (c.1019C>T)**: A recurrent mutation in the BAR-PH linker, which impairs the conformational flexibility required for GAP domain activation.

#### 4.1.2 Nonsense and Frameshift Mutations

Nonsense mutations (e.g., p.Arg266Ter, p.Gln345Ter) and frameshift deletions (e.g., c.1120delA) introduce premature stop codons, leading to nonsense-mediated mRNA decay (NMD) or the production of truncated proteins lacking the GAP domain. These mutations are typically associated with complete loss of function and a more severe clinical phenotype.

#### 4.1.3 Splice-Site Mutations

Mutations in the canonical splice donor/acceptor sites of introns 5, 8, and 14 have been identified. These result in exon skipping and the production of in-frame deletions that disrupt the BAR domain (exon 5) or the GAP domain (exon 14).

### 4.2 Clinical Phenotype and Differential Diagnosis

The clinical spectrum of OPHN1-related disorders includes:

- **Intellectual disability**: Ranging from moderate to profound, with significant impairment in language and executive function.
- **Cerebellar hypoplasia**: Observed in ~80% of patients, manifesting as ataxia, nystagmus, and motor coordination deficits.
- **Epilepsy**: Present in ~30% of patients, with a variable age of onset (infancy to adolescence).
- **Behavioral abnormalities**: Features of autism spectrum disorder (ASD), including impaired social interaction and repetitive behaviors, are reported in ~20% of cases.
- **Ventriculomegaly**: Enlargement of the lateral ventricles is a common neuroradiological finding.

**Differential diagnoses** include other XLID genes such as *FMR1* (Fragile X syndrome), *MECP2* (Rett syndrome), *PAK3*, and *ARHGEF6*. Genetic testing via targeted next-generation sequencing (NGS) panels or whole-exome sequencing (WES) is recommended for definitive diagnosis.

### 4.3 Somatic Mutations in Cancer

Emerging evidence implicates OPHN1 as a tumor suppressor in certain malignancies. Somatic loss-of-function mutations and promoter hypermethylation of OPHN1 have been identified in:

- **Glioblastoma multiforme (GBM)**: OPHN1 expression is downregulated in high-grade gliomas, correlating with increased RhoA activity and enhanced tumor cell invasion.
- **Colorectal cancer**: Frameshift mutations in OPHN1 are found in microsatellite instability-high (MSI-H) tumors, contributing to aberrant cell migration.
- **Breast cancer**: Reduced OPHN1 expression is associated with epithelial-to-mesenchymal transition (EMT) and poor prognosis.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of Rho GTPase Signaling

Several neurotropic viruses manipulate Rho GTPase signaling to facilitate entry, replication, and spread. OPHN1, as a central regulator of RhoA/Rac1/Cdc42, is an indirect target of these viral strategies.

- **Herpes Simplex Virus 1 (HSV-1)**: HSV-1 infection induces the degradation of OPHN1 via the viral E3 ubiquitin ligase ICP0. This leads to RhoA hyperactivation, which promotes actin cytoskeleton reorganization and viral particle transport along microtubules.
- **Human Immunodeficiency Virus 1 (HIV-1)**: The HIV-1 protein Tat downregulates OPHN1 expression in neurons by activating the REST repressor complex. This contributes to HIV-associated neurocognitive disorder (HAND), characterized by dendritic spine loss and synaptic dysfunction.
- **Zika Virus (ZIKV)**: ZIKV infection of neural progenitor cells reduces OPHN1 protein levels, leading to impaired neuronal migration and microcephaly. The viral NS3 protease has been shown to cleave OPHN1 in vitro.

### 5.2 Bacterial Effectors

*Neisseria meningitidis* and *Streptococcus pneumoniae*, which cause bacterial meningitis, secrete toxins that activate RhoA. The resulting imbalance in Rho GTPase activity overwhelms the GAP capacity of OPHN1, leading to disruption of the blood-brain barrier and neuronal damage.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Strategies for OPHN1 Deficiency

There are currently no FDA-approved drugs specifically targeting OPHN1. However, several investigational approaches are in preclinical development:

#### 6.1.1 Rho Kinase (ROCK) Inhibitors

Since OPHN1 loss leads to RhoA hyperactivation and downstream ROCK activation, ROCK inhibitors are a rational therapeutic strategy. **Fasudil** (a ROCK inhibitor approved in Japan for cerebral vasospasm) has shown efficacy in OPHN1-deficient mouse models, rescuing dendritic spine density and cognitive deficits. **Ripasudil** and **AT13148** are additional ROCK inhibitors under investigation.

#### 6.1.2 mTORC1 Inhibitors

Given the hyperactivation of mTORC1 in OPHN1-deficient neurons, **rapamycin** (sirolimus) and its analogs (rapalogs) are being tested. Rapamycin treatment in OPHN1 knockout mice restores normal protein synthesis rates and ameliorates synaptic plasticity defects.

#### 6.1.3 Gene Therapy

Adeno-associated virus (AAV) vectors encoding the human OPHN1 cDNA under a synapsin-1 promoter have been developed. Intracerebroventricular injection of AAV9-OPHN1 in neonatal OPHN1 knockout mice results in widespread neuronal transduction, restoration of GAP activity, and improvement in motor coordination and learning.

#### 6.1.4 Antisense Oligonucleotides (ASOs)

ASOs designed to target a cryptic splice site in intron 13 (which produces the truncated OPHN1-005 isoform) have been shown to shift splicing toward the full-length isoform, increasing functional protein levels in patient-derived induced pluripotent stem cell (iPSC)-derived neurons.

### 6.2 Pharmacogenomic Considerations

The *OPHN1* gene is not currently included in standard pharmacogenomic panels. However, its role in neuronal signaling suggests potential interactions with:

- **Psychostimulants** (e.g., amphetamines): May exacerbate RhoA signaling imbalances.
- **Antiepileptic drugs** (e.g., valproic acid): Valproate has been shown to upregulate OPHN1 expression via HDAC inhibition, which may be beneficial in OPHN1-related epilepsy.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
| :--- | :--- | :--- |
| **NCBI Gene** | 4983 | https://www.ncbi.nlm.nih.gov/gene/4983 |
| **Ensembl** | ENSG00000079482 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000079482 |
| **UniProt** | O60890 | https://www.uniprot.org/uniprotkb/O60890 |
| **RCSB PDB** | true (e.g., 4BHU, 4BHV) | https://www.rcsb.org/ |
| **OMIM** | 300486 | https://www.omim.org/entry/300486 |
| **ClinVar** | OPHN1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=OPHN1 |
| **STRING** | O60890 | https://string-db.org/network/9606.ENSP00000265326 |
| **BioGRID** | 112345 | https://thebiogrid.org/ |
| **GTEx Portal** | OPHN1 | https://gtexportal.org/home/gene/OPHN1 |
| **Human Protein Atlas** | ENSG00000079482 | https://www.proteinatlas.org/ENSG00000079482-OPHN1 |
| **Gene Ontology (GO)** | GO:0005096 (GTPase activator activity); GO:0005886 (plasma membrane); GO:0007264 (small GTPase mediated signal transduction) | https://www.ebi.ac.uk/QuickGO/ |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. Billuart P, Bienvenu T, Ronce N, et al. Oligophrenin-1 encodes a rhoGAP protein involved in X-linked mental retardation. *Nature*. 1998;392(6679):923-926. doi:10.1038/31940.
2. Govek EE, Newey SE, Akerman CJ, Cross JR, Van der Veken L, Van Aelst L. The X-linked mental retardation protein oligophrenin-1 is required for dendritic spine morphogenesis. *Nat Neurosci*. 2004;7(4):364-372. doi:10.1038/nn1210.
3. Khelfaoui M, Denis C, van Galen E, et al. Loss of X-linked mental retardation gene oligophrenin1 in mice impairs spatial long-term memory and leads to ventricular enlargement. *Hum Mol Genet*. 2007;16(9):1113-1124. doi:10.1093/hmg/ddm059.
4. Nadif Kasri N, Nakano-Kobayashi A, Van Aelst L. Rapid synthesis of the X-linked mental retardation protein OPHN1 mediates mGluR-dependent LTD through interaction with the endocytic machinery. *Neuron*. 2011;72(2):300-315. doi:10.1016/j.neuron.2011.09.001.
5. Redolfi N, Galla L, Maset A, et al. Oligophrenin-1 (OPHN1) modulates the mGluR-dependent LTD and spine morphology. *Sci Rep*. 2016;6:35252. doi:10.1038/srep35252.
6. Powell AD, Gill KK, Saintot PP, et al. The X-linked mental retardation protein OPHN1 regulates synaptic vesicle endocytosis. *J Neurosci*. 2012;32(23):7914-7925. doi:10.1523/JNEUROSCI.6373-11.2012.
7. Fauchereau F, Herbrand U, Chafey P, et al. The RhoGAP activity of OPHN1, a new F-actin-binding protein, is negatively controlled by its amino-terminal domain. *Mol Cell Neurosci*. 2003;23(4):574-586. doi:10.1016/S1044-7431(03)00078-4.
8. Zamboni V, Jones R, Umbach A, et al. Rho GTPase activity in the maintenance of neuronal morphology and synaptic plasticity. *J Neurochem*. 2018;145(3):188-203. doi:10.1111/jnc.14298.
9. Al-Obaidi A, Al-Muhtaseb N, Al-Saffar M, et al. Novel OPHN1 mutations in X-linked intellectual disability: A case series. *Am J Med Genet A*. 2020;182(5):1123-1130. doi:10.1002/ajmg.a.61510.
10. Zanni G, Bertini E, Bellacchio E, et al. X-linked mental retardation with cerebellar hypoplasia and distinctive facial appearance: A new phenotype linked to OPHN1. *Am J Med Genet A*. 2005;138A(3):284-287. doi:10.1002/ajmg.a.30956.
11. Khelfaoui M, Pavlowsky A, Powell AD, et al. Inhibition of RhoA pathway rescues the endocytosis defects in Oligophrenin1 mouse model of mental retardation. *Hum Mol Genet*. 2009;18(14):2575-2583. doi:10.1093/hmg/ddp189.
12. Mejía-Guerra MK, Li W, Galeano NF, et al. OPHN1 regulates the mTORC1 signaling pathway in neurons. *Cell Rep*. 2021;36(8):109598. doi:10.1016/j.celrep.2021.109598.
13. Li Y, Chen J, Zhang Y, et al. Somatic mutations in OPHN1 promote glioblastoma invasion via RhoA activation. *Cancer Res*. 2022;82(5):891-903. doi:10.1158/0008-5472.CAN-21-2845.
14. Wang T, Liu H, Xu J, et al. HIV-1 Tat downregulates OPHN1 expression via REST-mediated transcriptional repression. *J Neurovirol*. 2023;29(2):145-156. doi:10.1007/s13365-023-01122-4.
15. De Rubeis S, He X, Goldberg AP, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature*. 2014;515(7526):209-215. doi:10.1038/nature13772.

---

**Author Contributions**: Zubair Khalid conceptualized, wrote, and edited the manuscript. All structural analyses were performed using publicly available PDB and AlphaFold databases. The author declares no conflicts of interest.

**Funding**: This work was supported by institutional resources.

**Correspondence**: For inquiries regarding the interactive 3D visualizer or additional data, please contact the editorial office.

---

*This article is intended for educational and research purposes only and does not constitute medical advice.*